These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 17703136

  • 1. Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats.
    Tawara S, Fukumoto Y, Shimokawa H.
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):195-200. PubMed ID: 17703136
    [Abstract] [Full Text] [Related]

  • 2. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats.
    Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K, Takeshit A.
    Circ Res; 2004 Feb 20; 94(3):385-93. PubMed ID: 14670839
    [Abstract] [Full Text] [Related]

  • 3. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice.
    Abe K, Tawara S, Oi K, Hizume T, Uwatoku T, Fukumoto Y, Kaibuchi K, Shimokawa H.
    J Cardiovasc Pharmacol; 2006 Dec 20; 48(6):280-5. PubMed ID: 17204906
    [Abstract] [Full Text] [Related]

  • 4. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats.
    Jiang BH, Tawara S, Abe K, Takaki A, Fukumoto Y, Shimokawa H.
    J Cardiovasc Pharmacol; 2007 Feb 20; 49(2):85-9. PubMed ID: 17312448
    [Abstract] [Full Text] [Related]

  • 5. Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats.
    Elias-Al-Mamun M, Satoh K, Tanaka S, Shimizu T, Nergui S, Miyata S, Fukumoto Y, Shimokawa H.
    Circ J; 2014 Feb 20; 78(4):967-76. PubMed ID: 24553194
    [Abstract] [Full Text] [Related]

  • 6. Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension.
    Akagi S, Nakamura K, Matsubara H, Kondo M, Miura D, Matoba T, Egashira K, Ito H.
    J Cardiovasc Pharmacol; 2016 Apr 20; 67(4):290-8. PubMed ID: 26745002
    [Abstract] [Full Text] [Related]

  • 7. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
    Jasińska-Stroschein M, Owczarek J, Plichta P, Orszulak-Michalak D.
    Pharmacology; 2014 Apr 20; 93(3-4):145-50. PubMed ID: 24662671
    [Abstract] [Full Text] [Related]

  • 8. Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats.
    Zhang WH, Liu CP, Zhang YJ, Ji YQ, Lu WX, Zeng Q.
    Scand Cardiovasc J; 2012 Dec 20; 46(6):374-80. PubMed ID: 22971207
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Role of Rho-kinase signaling and endothelial dysfunction in modulating blood flow distribution in pulmonary hypertension.
    Schwenke DO, Pearson JT, Sonobe T, Ishibashi-Ueda H, Shimouchi A, Kangawa K, Umetani K, Shirai M.
    J Appl Physiol (1985); 2011 Apr 20; 110(4):901-8. PubMed ID: 21212241
    [Abstract] [Full Text] [Related]

  • 15. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.
    Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF.
    Circ Res; 2007 Mar 30; 100(6):923-9. PubMed ID: 17332430
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency.
    Gupta N, Rashid J, Nozik-Grayck E, McMurtry IF, Stenmark KR, Ahsan F.
    Mol Pharm; 2017 Mar 06; 14(3):830-841. PubMed ID: 28165252
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.